Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.54 USD | +1.24% | -2.97% | -36.57% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.57% | 188M | |
+8.38% | 220B | |
+15.78% | 198B | |
+23.68% | 148B | |
+31.27% | 112B | |
+4.14% | 66.17B | |
+14.19% | 52.47B | |
+4.70% | 50.77B | |
-3.93% | 38.97B | |
-0.47% | 35.13B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Wells Fargo Increases Price Target on NeuroPace to $16 From $9, Maintains Equalweight Rating